Health

Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot’s Side Effects

TWSJ·3h ago·3 min read

Photograph via The Wall Street Journal

RSS SUMMARY · AGGREGATED FROM TWSJ

Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.

The full story continues on The Wall Street Journal.

Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.

Read on The Wall Street Journal →

The Source

The full story continues on The Wall Street Journal.

TWSJ

Amazon Enters Agreement With Corning for Optical Fiber for Data Centers

The Only Thing Hotter Than the Knicks Is Their Stock Price

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Wix.com Slashes 20% of Staff, Lowers Outlook as Restructuring Continues

On this beat

Weight loss drug maker sinks 25% after new safety data spooks investors

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

Life After A Spinal Injury: A Guide to Physical And Mental Recovery

Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch